Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL2515063

O/N=C(/Nc1ccc(F)c(Br)c1)c1nonc1NCc1ccc(CN2CCOCC2)cc1.O=C(O)C(F)(F)F

nearest known ligand 0.47

Full drug profile on Sugi Atlas →

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 10/20 0.47
NAMPT P43490 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.40
KCNJ1 P48048 1/20 0.40
KCNH2 Q12809 1/20 0.40
NPC1 O15118 4/20 0.40
RAB9A P51151 3/20 0.40
HIF1A Q16665 2/20 0.40
EPAS1 Q99814 2/20 0.40
TP53 P04637 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
GPR6 P46095 1/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL2515067 1.00 IDO1 (0.47) IDO1NAMPTL3MBTL1KCNJ1KCNH2
SCHEMBL2519682 0.94 IDO1 (0.49) IDO1NAMPTKCNH2HIF1AEPAS1
SCHEMBL2519685 0.94 IDO1 (0.49) IDO1NAMPTKCNH2HIF1AEPAS1
Trifluoroacetic Acid SCHEMBL6046554 0.92 IDO1 (0.46) IDO1NAMPTGPR6
Trifluoroacetic Acid SCHEMBL6046557 0.92 IDO1 (0.46) IDO1NAMPTGPR6
Trifluoroacetic Acid SCHEMBL2515807 0.92 IDO1 (0.46) IDO1NAMPTGPR6
Trifluoroacetic Acid SCHEMBL2515813 0.92 IDO1 (0.46) IDO1NAMPTGPR6
Trifluoroacetic Acid SCHEMBL2515043 0.91 IDO1 (0.46) IDO1NAMPTKCNH2GPR6
Trifluoroacetic Acid SCHEMBL2515038 0.91 IDO1 (0.46) IDO1NAMPTKCNH2GPR6
Trifluoroacetic Acid SCHEMBL2519441 0.90 HIF1A (0.49) IDO1NPC1RAB9AHIF1AEPAS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11192868-B2 Modulators of indoleamine 2,3-dioxygenase and methods of using the same INCYTE CORPORATION (US) 2021-12-07 US disclosed
US-20190210985-A1 MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF USING THE SAME INCYTE CORPORATION 2019-07-11 US disclosed
US-10208002-B2 Modulators of indoleamine 2,3-dioxygenase and methods of using the same INCYTE CORPORATION (US) 2019-02-19 US disclosed
US-20180030006-A1 MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF USING THE SAME INCYTE CORPORATION 2018-02-01 US disclosed
EP-3085697-A1 MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF USING THE SAME Incyte Holdings Corporation (US) 2016-10-26 EP disclosed
EP-2559690-B1 Modulators of indoleamine 2,3-dioxygenase and methods of using the same INCYTE HOLDINGS CORP (US) 2016-03-30 EP disclosed
US-20140377292-A1 MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF USING THE SAME INCYTE CORPORATION (US) 2014-12-25 US disclosed
US-8846726-B2 Modulators of indoleamine 2,3-dioxygenase and methods of using the same INCYTE CORPORATION (US) 2014-09-30 US disclosed
US-20130123246-A1 MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF USING THE SAME INCYTE CORPORATION (US) 2013-05-16 US disclosed
EP-2559690-A1 Modulators of indoleamine 2,3-dioxygenase and methods of using the same Incyte Corporation (US) 2013-02-20 EP disclosed
US-8372870-B2 Modulators of indoleamine 2,3-dioxygenase and methods of using the same for treating cancer INCYTE CORPORATION (US) 2013-02-12 US disclosed
EP-1879573-B1 MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF USING THE SAME INCYTE CORP (US) 2012-12-19 EP disclosed
US-20110311479-A1 MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF USING THE SAME INCYTE CORPORATION, A DELAWARE CORPORATION 2011-12-22 US disclosed
US-8034953-B2 Modulators of indoleamine 2,3-dioxygenase and methods of using the same INCYTE CORPORATION (US) 2011-10-11 US disclosed
US-20060258719-A1 Modulators of indoleamine 2,3-dioxygenase and methods of using the same INCYTE CORPORATION 2006-11-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10208002-B2 Modulators of indoleamine 2,3-dioxygenase and methods of using the same IDO1, IDO2, INMT IDO1 1/4885NAMPT 219/4885L3MBTL1 4708/4885
US-20180030006-A1 MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF USING THE SAME IDO1, IDO2, INMT IDO1 1/4885NAMPT 219/4885L3MBTL1 4708/4885
US-11192868-B2 Modulators of indoleamine 2,3-dioxygenase and methods of using the same IDO1, IDO2, INMT IDO1 1/4885NAMPT 219/4885L3MBTL1 4708/4885
US-20060258719-A1 Modulators of indoleamine 2,3-dioxygenase and methods of using the same IDO1, IDO2, INMT IDO1 1/4885NAMPT 219/4885L3MBTL1 4708/4885
US-20110311479-A1 MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF USING THE SAME IDO1, IDO2, INMT IDO1 1/4885NAMPT 219/4885L3MBTL1 4708/4885
US-20190210985-A1 MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF USING THE SAME IDO1, IDO2, INMT IDO1 1/4885NAMPT 219/4885L3MBTL1 4708/4885
US-20140377292-A1 MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF USING THE SAME IDO1, IDO2, INMT IDO1 1/4885NAMPT 219/4885L3MBTL1 4708/4885
US-20130123246-A1 MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF USING THE SAME IDO1, IDO2, INMT IDO1 1/4885NAMPT 219/4885L3MBTL1 4708/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.